http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-RE33252-E
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-246 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-24 |
| filingDate | 1986-07-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 1990-07-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1990-07-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-RE33252-E |
| titleOfInvention | Hybridoma antibody which inhibits Interleukin 2 activity |
| abstract | A process for producing anti-IL-2 antibody from hybridoma cells generated by fusing activated, IL-2 immunized, murine lymphocyte cells with neoplastic murine myeloma cells. Fusion is accomplished by mixing the two cell lines together in the presence of a fusing agent. After fusion, the hybridoma cells are cultured in vitro in a supplemented tissue culture medium to thereby produce anti-IL-2 antibody. Also, the hybridoma cells are cloned by a limiting dilution procedure to isolate even more potent sources of anti-IL-2 antibody. Anti-IL-2 antibody is then purified from either tissue culture medium conditioned by hybridoma cells, or from peritoneal ascites of mice challenged with hybridoma cells. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11083778-B2 |
| priorityDate | 1981-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 101.